News : nail

The Seven Deadly Sins

1/30/2012 2:12 PM EST - IBISWorld

Although Cardinal sins like gluttony and lust have a fiery fate for offenders, they’re quite the industry moneymakers
By IBISWorld Industry Analysts Josh McBee and Agata Kaczanowska

Whether through personal religious studies, music, artwork or film, most people are familiar with the vices that make up the “seven deadly sins,” or Cardinal Sins. While the origination and descriptions vary from source to source,...

MOBERG DERMA SIGNS LETTER OF INTENT FOR DISTRIBUTION IN THE UNITED STATES

3/29/2011 3:00 AM EST - MOBERG DERMA AB

Moberg Derma AB (publ) has entered into a letter of intent for distribution in the United States. The letter of intent includes Emtrix® – a product for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. The intention is to give the distributor an exclusive right to market and sell Emtrix® in the U.S.
"Already the first quarter after launch, Emtrix® is the...

MOBERG DERMA SIGNS AGREEMENT FOR EMTRIX® IN PORTUGAL AND 10 MARKETS IN AFRICA AN...

11/11/2010 3:30 AM EST - MOBERG DERMA AB

Moberg Derma AB today announced that a distribution agreement has been entered into with Laboratorio EDOL Produtos Farmaceuticos S.A. for Emtrix® – Moberg Derma’s product for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement EDOL is granted exclusive rights to market and sell Emtrix® in Portugal and ten markets in Africa and Central America. Moberg Derma will...

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT FOR EMTRIX™ IN ADDITIONAL 8 COUNTRIES

6/18/2010 3:45 AM EST - MOBERG DERMA AB

Moberg Derma AB, Sweden, today announced a commercial agreement for the Middle East. The agreement covers distribution in eight countries for Moberg Derma’s novel topical nail product Emtrix™ – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while the distributor will be responsible for registration...

MOBERG DERMA OBTAINS APPROVAL FOR NOVEL TREATMENT FOR NAIL DISEASES

4/12/2010 3:31 AM EST - MOBERG DERMA AB

Moberg Derma AB today announced that CE-mark has been granted for the company’s first approved medical device product, used for the treatment of discolored and damaged nails, for example caused by nail fungus (onycomycosis) or nail psoriasis. The CE mark provides authorization to market and sell the product in the EU/EEA.
“The approval is a result of focused development work during several years and is an...

MOBERG DERMA SECURED SEK 35 MILLION IN NEW SHARE ISSUE

8/24/2009 2:00 AM EST - MOBERG DERMA AB

The pharmaceutical company Moberg Derma recently secured SEK 35 million in a new share issue. Both existing and new shareholders subscribed for shares in the issue. More than SEK 100 million has now been raised for its operations since the company was established in March 2006.
“We are very pleased with the interest shown by investors what has been a difficult market climate in recently. The new share issue has...

MOBERG DERMA REPORTS POSITIVE PHASE III RESULTS FOR K101 AGAINST NAIL FUNGUS

11/20/2008 8:50 AM EST - MOBERG DERMA AB

Moberg Derma AB reports today positive results from a phase III clinical study for K101 against nail fungus (onychomycosis). In the study, almost 500 patients were treated during six months with K101 or a placebo. The results showed that significantly more patients receiving K101 were cured of their fungal infection (p=0.001). The patients' subjective evaluation of the treatment effect revealed distinct benefits...